Abciximab 1993-2001
ReoPro Trials - Free PowerPoint Slides
http://www.clinicaltrialresults.org/ua/abciximab/abciximab_home.htm
ESC 2001 Meeting Coverage
AHA 2001 Meeting Coverage
Efficacy and safety of tenecteplase in
combination with enoxaparin, abciximab, or unfractionated heparin: the
ASSENT-3 randomised trial in acute myocardial infarction
Lancet 2001;358:605-13
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11530146
THE LANCET/THEHEART.ORG
PRESENT
ASSENT 3: tenecteplase in combination with enoxaparin, abciximab, or
unfractionated heparin
http://www.theheart.org/index.cfm?doc_id=25125
Dr Frans Van de Werf reviews the clinical implications of ASSENT 3 with
Drs Paul Armstrong, Christopher Granger, and Lars Wallentin.
The ASSENT 3 results, which were published in the August 25 issue of The
Lancet, compared 3 possible therapeutic combinations with tenecteplase:
enoxaparin, abciximab, or unfractionated heparin
GUSTO V — the first major trial
evaluating thrombolysis plus GP IIb/IIIa blockade in MI patients
http://www.theheart.org/index.cfm?doc_id=23550
Originally netcast on June 14, 2001
Drs Robert Califf, Michael Lincoff, Eric Topol, and Frans
Van de Werf review the clinical implications of GUSTO V. GUSTO V
is the first large-scale trial to compare the use of a GP IIb/IIIa blocker in
combination with a thrombolytic; 16 588 AMI patients were randomized.
Combination fibrinolytic and GP IIb/IIIa
blocker therapy — where next?
http://www.theheart.org/index.cfm?doc_id=24200
The world has scarcely had time to digest the results of GUSTO V, but already
plans are afoot for the next wave of studies. [July 18 2001]
SELF-PACED LEARNING
Anti-inflammatory effects of abciximab
With slide / Some of the long-term benefits of the GP IIb/IIIa
receptor inhibitor abciximab after PCI may be related to an anti-inflammatory
effect. [July 11]
http://www.theheart.org/index.cfm?doc_id=24126
Reperfusion therapy for acute myocardial
infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy
and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised
trial
Topol EJ.
Lancet 2001;357:1905-14
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11425410
A total of 16 588 patients in the first six hours of evolving ST segment
elevation MI were randomly assigned standard dose reteplase (n = 8260) or half
dose reteplase and full dose abciximab (n = 8328). There was no difference in
death rates at 30 days, as the small reduction in death/MI rates with dual
treatment was balanced by increased bleeding related complications.
Abciximab plus low-dose thrombolitics for
AMI
Two studies indicate that a combination of abciximab (ReoPro) and a
half-dose thrombolytic may be an alternative treatment for acute myocardial
infarction (AMI).
http://cardiology.medscape.com/42293.rhtml?srcmp=card-090701
Comparison of two platelet glycoprotein
IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic
events with percutaneous coronary revascularization
Topol EJ, et al. for the TARGET Investigators
N Engl J Med 2001;344:1888-94
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11419425
Comment
Comparative 30-day economic and clinical
outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective
percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost
Evaluation (PRICE) Trial
Am Heart J 2001;141:402-9
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11231437
Platelet glycoprotein IIb/IIIa inhibition
with coronary stenting for acute myocardial infarction
Montalescot G, et al. for the ADMIRAL Investigators
N Engl J Med 2001;344:1895-903
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11419426
Comment
Effect of glycoprotein IIb/IIIa receptor
blocker abciximab on outcome in patients with acute coronary syndromes without
early coronary revascularisation: the GUSTO IV-ACS randomised trial
Simoons ML.
Lancet 2001;357:1915-24
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11425411
Comment
Abciximab and early adjunctive percutaneous
coronary intervention are associated with improved ST-segment resolution after
thrombolysis: Observations from the
TIMI 14 Trial
de Lemos JA, et al.
Am Heart J 2001;141:592-8
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11275925
A strategy that uses a combination reperfusion regimen that includes abciximab,
followed by early adjunctive PCI, is associated with greater ST-segment
resolution, which may reflect enhanced tissue level and microvascular perfusion.
Hemorrhagic and vascular complications after
percutaneous coronary intervention with adjunctive abciximab
Cote AV, et al.
Mayo Clin Proc 2001;76:890-6
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11560299
Long-term mortality benefit with abciximab
in patients undergoing percutaneous coronary intervention
Anderson KM, et al.
J Am Coll Cardiol 2001;37:2059-65
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11419888
The evidence from 9,290 randomized PCI patients shows a mortality benefit
provided by abciximab bolus plus 12-h infusion.
AVAILABLE FOR
SELF-PACED LEARNING
Long-Term Benefits of Pharmacologic Therapy in PCI
http://www.theheart.org/index.cfm?doc_id=24284
CME credit: 1 hour, category 1
New provocative data provide updated information on the long-term benefits of
pharmacologic therapy in PCI. Drs Eric Topol, David Moliterno, and
Marc Cohen discuss these exciting data.
Abciximab readministration: results of the
ReoPro Readministration Registry
Tcheng JE, et al.
Circulation 2001;104:870-5
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11514371
The results, including overall rates of thrombocytopenia, were consistent with
randomized clinical trials of first abciximab treatment. However, there was a
shift from mild to profound thrombocytopenia, and cases of delayed presentation
and of recurrent thrombocytopenia were seen.
Effects of Abciximab on the architecture of
platelet-rich clots in patients with acute myocardial infarction undergoing
primary coronary intervention
Collet JP, et al.
Circulation 2001;103:2328-31
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11352878
Abciximab dramatically reduces platelet aggregate size and increases the fibrin
accessibility of ex vivo PRC in AMI patients. These modifications could
participate in the better coronary artery patency observed with abciximab.
Effectiveness and safety of abciximab after
failed thrombolytic therapy
Cantor WJ, et al.
Am J Cardiol 2001;87:439-42, A4
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11179529
Among 214 patients treated with abciximab within 24 hours of full-dose
thrombolytic therapy, major bleeding occurred in 50 patients (23%) and
intracranial hemorrhage occurred in 3 patients (1.4%). The independent
multivariate predictors of major bleeding were age (odds ratio [OR] 1.53/10
years, 95% CI 1.05 to 2.21, p = 0.03), time from thrombolytic to abciximab (OR
0.91/hour, 95% CI 0.83 to 0.99, p = 0.03), and intra-aortic balloon pump
insertion (OR 4.42, 95% CI 2.00 to 9.72, p = 0.0002).
Late-Breaking Clinical Trial
GUSTO IV ACS
Califf R Presented at ESC 2000 Meeting
Additional Comments: Click here Full slide set by Robert
Califf, M.D. Click ere or here
No ACS Benefit for Abciximab in GUSTO IV-ACS. This trial enrolled 7,800 patients with
ACS, with patients randomized to either placebo or abciximab. Treatment with abciximab for either 24 or 48 hours on top of aspirin and unfractionated or low molecular weight heparin does not reduce death or MI in patients with ACS not undergoing early revascularization
Click here to view the full article
EPIC, EPILOG, EPISTENT - Abciximab reduces mortality in diabetics following percutaneous coronary intervention
Bhatt DL et al.
J Am Coll Cardiol 2000;35:922-8
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0010732889
Abciximab decreases the mortality of diabetic patients to the level of placebo-treated nondiabetic
patients. This beneficial effect is noteworthy in those diabetic patients who are also hypertensive and obese and in diabetics undergoing multivessel
intervention. Besides its potential role in reducing repeat intervention for stented diabetic
patients, abciximab therapy should be strongly considered in diabetic patients undergoing PCI to improve their
survival.
STOPAMI - Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. STOPAMI Investigators
Schomig A et al. for the STOPAMI Investigators
N Engl J Med 2000;343:385-91
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0010933737
In patients with acute myocardial infarction, coronary stenting plus abciximab leads to a greater degree of myocardial salvage and a better clinical outcome than does fibrinolysis with a tissue plasminogen
activator.
Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction
Neumann FJ, et al.
J Am Coll Cardiol 2000;35:915-21
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0010732888
In patients undergoing stenting following AMI, abciximab exerted beneficial effects by substantially reducing the 30-day rate of major adverse cardiac
events. During one-year follow-up, there was no additional benefit from a reduction in TLR nor did abciximab reduce angiographic
restenosis.
The benefit of abciximab in percutaneous coronary revascularization is not device-specific
Bhatt DL et al.
Am J Cardiol 2000;85:1060-4
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0010781752
Pooled data from the 5 placebo-controlled trials of abciximab during PCI demonstrate that a decrease in death and MI is achieved with abciximab regardless of the type of device used
(PTCA alone, stenting, or DCA), without an increase in significant bleeding
complications..
TIMI 14 - Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial
infarction.
de Lemos JA et al.
Circulation 2000;101:239-43
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0010645918
In the TIMI 14 trial, a dose-ranging angiographic study, combined therapy with abciximab plus reduced-dose tPA enhanced the speed and efficacy of epicardial
reperfusion. In addition, it improved myocardial (microvascular) reperfusion, as reflected in greater ST-segment
resolution. This finding may translate into improved clinical outcomes by enhancing myocardial
salvage.
Effects of abciximab, ticlopidine, and combined
Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty
Fredrickson BJ et al.
Circulation 2000;101:1122-9
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0010715258
Combined therapy with abciximab and ticlopidine has a prolonged inhibitory effect on mural thrombosis formation relative to either treatment alone.
Further, this study demonstrated an unexpected effect of abciximab in enhancing P-selectin- mediated leukocyte
adhesion.
Unexpected Mortality Reduction with Abciximab for In-Stent Restenosis
Mukherjee D || Ellis SG
J Invasive Cardiol 2000;12:540-544
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0011060563.
Click here to view the full article
At 1- year follow-up, there was a significantly lower incidence of myocardial infarction (2.5% versus 5.3%; p < 0.05) and lower mortality (1.2% versus 5.8%; p < 0.01) in the abciximab-treated
group. There was no difference in the incidence of revascularization. The findings of a lowered mortality and myocardial infarction rate with abciximab warrants further prospective study in patients with in-stent
restenosis.
Editorial
Avoidance of Adverse Events in Restenotic Lesions with Abciximab?
Linnemeier TJ
J Invasive Cardiol 2000;12:545-546
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0011060564
Click here to view the full article
Clinical outcomes following "Rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty
Fuchs S || Leon MB
J Invasive Cardiol 2000;12:497-501
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0011022207
Click here to view the full article
Rescue administration of abciximab is associated with relatively low in-hospital complications and favorable long-term outcome in patients with sub-optimal angioplasty results and/or procedure-related
complications, although peri-procedural non-Q wave MI rate is high.
Editorial
"Rescue" platelet GP IIb/IIIa inhibitor therapy in percutaneous coronary intervention: bailing out of a sunken ship
Kandzari DE || Sketch MH Jr.
J Invasive Cardiol 2000;12:502-4
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0011022208
Click here to view the full article
Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts
Barsness GW et al.
Am Heart J 2000;139:824-9
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0010783216
Click here to view the full article
Local abciximab delivery before percutaneous intervention for de novo SVG stenoses followed by intravenous infusion is associated with significantly reduced thrombus
burden, significantly improved percent diameter stenosis, and excellent acute procedural
results.
Antithrombotic effects of abciximab
Hayes R, et al.
Am J Cardiol 2000;85:1167-72.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=10801995
Clinical outcomes following
"rescue" administration of abciximab in patients undergoing
percutaneous coronary angioplasty
Fuchs S, et al.
J Invasive Cardiol 2000;12:497-501.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=11022207
In vivo demonstration of an antithrombin
effect of abciximab
Ambrose JA, et al.
Am J Cardiol 2000;86:150-2.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=10913474
Clinical risk factors for ischemic
complications after percutaneous coronary interventions: results from the EPIC
trial. The EPIC Investigators
Thel MC, et al.
Am Heart J 1999;137:264-73.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9924160
Sustained suppression of ischemic
complications of coronary intervention by platelet GP IIb/IIIa blockade with
abciximab: one-year outcome in the EPILOG trial.Evaluation in PTCA to Improve
Long-term Outcome with abciximab GP IIb/IIIa blockade
Lincoff AM, et al.
Circulation 1999;99:1951-8.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=10208997
Effects of platelet glycoprotein IIb/IIIa
inhibition with abciximab on thrombin generation and activity during
percutaneous coronary intervention
Dangas G, et al.
Am Heart J 1999;138:49-54.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=10385763
Complications associated with combined use
of abciximab and an intracoronary thrombolytic agent (urokinase or tissue-type
plasminogen activator)
Yaryura RA, et al.
Am J Cardiol 1998;82:518-9.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9723644
Evolution of improved antithrombotic and
antiplatelet agents: genesis of the Comparison of Abciximab Complications with
Hirulog [and back-Up Abciximab] Events Trial (CACHET)
Topol EJ.
Am J Cardiol 1998;82:63P-68P.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9809894
Preferential benefit of platelet
glycoprotein IIb/IIIa receptor blockade: specific considerations by device and
disease state
Kereiakes DJ.
Am J Cardiol 1998;81:49E-54E.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9551595
Platelet glycoprotein IIb/IIIa receptor
blockade with abciximab reduces ischemic complications in patients undergoing
directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to
Improve Long- term Outcome by c7E3 GP IIb/IIIa Receptor Blockade
Ghaffari S, et al.
Am J Cardiol 1998;82:7-12.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9671000
Reduction in complications of angioplasty
with abciximab occurs largely independently of baseline lesion morphology. EPIC
and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic
Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab
GPIIb/IIIa Receptor Blockade
Ellis SG, et al.
J Am Coll Cardiol 1998;32:1619-23.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9822087
Administration of abciximab during
percutaneous coronary intervention reduces both ex vivo platelet thrombus
formation and fibrin deposition: implications for a potential anticoagulant
effect of abciximab
Dangas G, et al.
Arterioscler Thromb Vasc Biol 1998;18:1342-9.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9714143
Occurrence and clinical significance of
thrombocytopenia in a population undergoing high-risk percutaneous coronary
revascularization. Evaluation of c7E3 for the Prevention of Ischemic
Complications (EPIC) Study Group
Berkowitz SD, et al.
J Am Coll Cardiol 1998;32:311-9.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9708455
Standard versus low-dose weight-adjusted
heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor
antibody fragment abciximab (c7E3 Fab) during percutaneous coronary
revascularization. PROLOG Investigators
Lincoff AM, et al.
Am J Cardiol 1997;79:286-91.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9036746
Rapid and simple platelet function assay to
assess glycoprotein IIb/IIIa receptor blockade
Coller BS, et al.
Circulation 1997;95:860-7.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9054743
Acute profound thrombocytopenia after C7E3
Fab (abciximab) therapy
Berkowitz SD, et al.
Circulation 1997;95:809-13.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9054735
In vitro effects of the platelet
glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting
time
Ammar T, et al.
Circulation 1997;95:614-7.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9024148
Platelet glycoprotein IIb/IIIa receptor
blockade and low-dose heparin during percutaneous coronary revascularization.
The EPILOG Investigators
N Engl J Med 1997;336:1689-96.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9182212
More evidence for a beneficial effect of
platelet glycoprotein IIb/IIIa- blockade during coronary interventions. Latest
results from the EPILOG and CAPTURE trials
van de Werf F.
Eur Heart J 1996;17:325-6.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8737200
Antithrombotic assessment of the effects of
combination therapy with the anticoagulants efegatran and heparin and the
glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of
coronary artery thrombosis
Shetler TJ, et al.
Circulation 1996;94:1719-25.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8840866
Inhibition of platelet-mediated, tissue
factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody.
Potential implications for the effect of c7E3 Fab treatment on acute thrombosis
and "clinical restenosis"
Reverter JC, et al.
J Clin Invest 1996;98:863-74.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8698879
Effects of platelet glycoprotein IIb/IIIa
receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and
six-month outcomes after percutaneous transluminal coronary angioplasty for
acute myocardial infarction. EPIC investigators
Lefkovits J, et al.
Am J Cardiol 1996;77:1045-51.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8644655
Increased risk of non-Q wave myocardial
infarction after directional atherectomy is platelet dependent: evidence from
the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications
Lefkovits J, et al.
J Am Coll Cardiol 1996;28:849-55.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8837559
Differential dose-response to oral
xemilofiban after antecedent intravenous abciximab. Administration for complex
coronary intervention
Kereiakes DJ, et al.
Circulation 1996;94:906-10.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8790024
Effect of platelet glycoprotein IIb/IIIa
integrin blockade on activated clotting time during percutaneous transluminal
coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of
c7E3 Fab in the Prevention of Ischemic Complications trial
Moliterno DJ, et al.
Am J Cardiol 1995;75:559-62.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7887377
Shear-induced platelet aggregation is
inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody
fragment, c7E3 Fab, in patients undergoing coronary angioplasty
Konstantopoulos K, et al.
Circulation 1995;91:1427-31.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7867183
An overview of the results of the EPIC trial
Califf RM, et al.
Eur Heart J 1995;16 Suppl L:43-9.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8869018
Bleeding complications with the chimeric
antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing
percutaneous coronary intervention. EPIC Investigators
Aguirre FV, et al.
Circulation 1995;91:2882-90.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7796496
Randomised trial of coronary intervention
with antibody against platelet IIb/IIIa integrin for reduction of clinical
restenosis: results at six months. The EPIC Investigators
Topol EJ, et al.
Lancet 1994;343:881-6.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7908357
Pharmacodynamics of chimeric glycoprotein
IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary
angioplasty
Tcheng JE, et al.
Circulation 1994;90:1757-64.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7923659
Effects of profound platelet inhibition with
c7E3 before coronary angioplasty on complications of coronary bypass surgery.
EPIC Investigators. Evaluation Prevention of Ischemic Complications
Boehrer JD, et al.
Am J Cardiol 1994;74:1166-70.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=7977081
Cyclic flow variations after coronary
angioplasty in humans: clinical and angiographic characteristics and elimination
with 7E3 monoclonal antiplatelet antibody
Anderson HV, et al.
J Am Coll Cardiol 1994;23:1031-7.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8144764
Profound inhibition of platelet aggregation
with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the
Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study
Kleiman NS, et al.
J Am Coll Cardiol 1993;22:381-9.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8335808
Safety and antiplatelet effect of murine
monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in
patients undergoing elective coronary angioplasty
Ellis SG, et al.
Coron Artery Dis 1993;4:167-75.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8269208
Lack of usefulness of prolonged bleeding
times in predicting hemorrhagic events in patients receiving the 7E3
glycoprotein IIb/IIIa platelet antibody. The TAMI Study Group
Bernardi MM, et al.
Am J Cardiol 1993;72:1121-5.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8237799